CellVoyant, a Bristol, UK-based AI-first biotechnology spin-out from the University of Bristol accelerating the development of new stem cell therapies, raised £7.6M in Seed funding.
The round was led by Octopus Ventures, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital.
The company intends to use the funds to scale the business, including doubling the team size over the next two years, expanding laboratory and experimental infrastructure, and advancing AI capabilities.
Led by Professor Rafael Carazo Salas, Founder and CEO, CellVoyant is an AI-first biotechnology company creating novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale.
FinSMEs
26/02/2024